Mode
Text Size
Log in / Sign up
Phase 3 N=219 Randomized Treatment

Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial

Myelofibrosis

Enrolled (actual)
219
Serious AEs
43.4%
Results posted
May 2012
Primary outcome: Primary: Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 48 — 28.5; 0 Percentage of Participants — p=<0.0001

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Ruxolitinib (Drug); Best Available Therapy (BAT) (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Novartis Pharmaceuticals
Primary completion
Mar 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 48
28.5; 0 <0.0001 sig
SECONDARY
Duration of Maintenance of Spleen Volume Reduction (Median)
3.22; NA
SECONDARY
Duration of Maintenance of Spleen Volume Reduction (Kaplan-Meier Estimates)
0.72; NA; 0.67; NA; 0.63; NA
SECONDARY
Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 24
31.9; 0
SECONDARY
Time to First at Least 35% Reduction in Spleen Volume From Baseline by Treatment (Primary Analysis)
0.23; 0; 0.67; 1; 0.87; 1
SECONDARY
Progression-free Survival (PFS)
1.6; 1.4
SECONDARY
Leukemia-free Survival (LFS)
NA; 4.1
SECONDARY
Overall Survival (OS)
NA; 4.1
SECONDARY
Percentage of Participants With Bone Marrow Histomorphology at Week 48 (Primary Analysis)
2.7; 0.0; 7.5; 2.7; 8.9; 6.8
SECONDARY
Bone Marrow Histomorphology
1; 1; 2; 1; 2; 0
SECONDARY
Duration of Follow-up by Treatment
16; 15; 21; 10; 9; 13

Summary

This was an open label, randomized study comparing the efficacy and safety of randomized 2:1 Ruxolitinib tablets versus best-available therapy, as selected by the investigator. The purpose was to compare the efficacy, safety and tolerability of Ruxolitinib (INC424/INCB018424) given twice daily to the best-available therapy, in subjects with primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (PPV-MF) or post essential thrombocythemia myelofibrosis (PET-MF).

Eligibility Criteria

Inclusion Criteria

  • Subjects must be diagnosed with PMF, PPV-MF or PET-MF according to the 2008 World Health Organization criteria
  • Subjects with MF requiring therapy must be classified as high risk OR intermediate risk level 2 according to the prognostic factors defined by the International Working Group
  • Subjects with an ECOG performance status of 0, 1, 2 or 3
  • Subjects with peripheral blood blast count of < 10%.
  • Subjects who have not previously received treatment with a JAK inhibitor

Exclusion Criteria

  • Subjects with a life expectancy of less than 6 months
  • Subjects with inadequate bone marrow reserve as demonstrated by specific clinical laboratory counts
  • Subjects with any history of platelet counts < 50,000/µL or ANC < 500/µL except during treatment for a myeloproliferative disorder or treatment with cytotoxic therapy for any other reason
  • Subjects with inadequate liver or renal function
  • Subjects with clinically significant bacterial, fungal, parasitic or viral infection which require therapy
  • Subjects with an active malignancy over the previous 5 years except specific skin cancers
  • Subjects with severe cardiac conditions
  • Subjects who have had splenic irradiation within 12 months
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00934544). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search